Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000458888 | SCV000541561 | likely benign | Brugada syndrome 8 | 2024-12-23 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002436380 | SCV002754335 | uncertain significance | Cardiovascular phenotype | 2024-04-09 | criteria provided, single submitter | clinical testing | The p.A101V variant (also known as c.302C>T), located in coding exon 1 of the HCN4 gene, results from a C to T substitution at nucleotide position 302. The alanine at codon 101 is replaced by valine, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004533142 | SCV004121547 | uncertain significance | HCN4-related disorder | 2023-04-28 | criteria provided, single submitter | clinical testing | The HCN4 c.302C>T variant is predicted to result in the amino acid substitution p.Ala101Val. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.047% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/15-73660310-G-A). Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004701486 | SCV005204988 | uncertain significance | not specified | 2024-06-09 | criteria provided, single submitter | clinical testing |